Quote | ArTara Therapeutics Inc. (NASDAQ:TARA)
Last: | $3.09 |
---|---|
Change Percent: | 0.27% |
Open: | $3.73 |
Close: | $3.09 |
High: | $3.74 |
Low: | $2.95 |
Volume: | 797,808 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | ArTara Therapeutics Inc. (NASDAQ:TARA)
2024-05-02 08:49:35 ET More on Protara Therapeutics Protara: A Bombed Out Biotech With A Very Positive Skew Protara Therapeutics jumps 23% on $45M oversubscribed private financing Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
Message Board Posts | ArTara Therapeutics Inc. (NASDAQ:TARA)
Subject | By | Source | When |
---|---|---|---|
OrbiMed Advisors now holds 6%+ .. Opaleye 25+, | stocksrising | investorshub | 02/15/2023 3:14:25 AM |
Opal almost at 25% ownership! Continue to scoop | stocksrising | investorshub | 12/28/2021 4:51:06 AM |
Opal continues open market accumulation around 7ish:)see recent | stocksrising | investorshub | 11/20/2021 7:13:30 AM |
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price | stocksrising | investorshub | 11/08/2021 1:23:47 PM |
True!! This piggy never holds its gains, but | stocksrising | investorshub | 10/14/2021 3:15:55 PM |
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TAR...